Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder

J Child Adolesc Psychopharmacol. 2010 Aug;20(4):347-53. doi: 10.1089/cap.2009.0126.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are usually well tolerated in the pediatric population, and widely used in the treatment of obsessive-compulsive disorder (OCD). Of the 51 pediatric patients with obsessive-compulsive disorder seen in our outpatient clinic between January 2009 and July 2009, 3 of them developed behavioral disinhibition after treatment with fluvoxamine. These cases are described and discussed in relation to the use of CYP2D6 and CYP2C19 pharmacogenetic testing in patients treated with serotonin-selective reuptake inhibitors.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Child
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP2D6 / metabolism
  • Fluvoxamine / adverse effects*
  • Fluvoxamine / therapeutic use
  • Humans
  • Impulsive Behavior / chemically induced*
  • Inhibition, Psychological
  • Male
  • Obsessive-Compulsive Disorder / drug therapy
  • Pharmacogenetics
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Serotonin Uptake Inhibitors
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP2D6
  • Fluvoxamine